Gimv

Founded 1980

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 159
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 94
Rounds per year 2.29
Lead investments 46
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.35
Exits 47
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Software
  • Therapeutics
Summary

Gimv is the famous VC, which was founded in 1980. The main office of represented VC is situated in the Antwerpen. The fund was located in Europe if to be more exact in Belgium.

The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neurotech, AgroSavfe, FIRE1 Among the most successful fund investment fields, there are Therapeutics, Enterprise Software. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gimv, startups are often financed by Sofinnova Partners, Novartis Venture Fund, 3i Group. The meaningful sponsors for the fund in investment in the same round are Neomed Management, Andera Partners, VI Partners AG. In the next rounds fund is usually obtained by Sofinnova Partners, Neomed Management, HBM Healthcare Investments AG.

Besides them, we counted 31 critical employees of this fund in our database.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. This Gimv works on 3 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2017. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations.

Read more

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

sofatutor

EdTech
Education
Online Portals
16 Mar 2021 Germany, Berlin

Kinaset Therapeutics

Health Care
Medical
Therapeutics
Early Stage Venture
40M30 Nov 2020 United States, " United States"}

Topas Therapeutics

Advanced Materials
Biotechnology
Chemical
Chemical Engineering
Early Stage Venture
25M19 Oct 2020 Germany, " Germany"}

AME

Manufacturing
Private Equity
02 Mar 2020 Netherlands, Eindhoven

JenaValve Technology

Health Care
Medical
Medical Device
Late Stage Venture
50M05 Feb 2020 Germany, Munich

General Fusion

Energy
Environmental Engineering
Renewable Energy
Late Stage Venture
65M16 Dec 2019 Canada, Burnaby

iSTAR Medical

Health Care
Manufacturing
Medical Device
Late Stage Venture
47M05 Sep 2019 Belgium, " Belgium"}

Biotalys

Agriculture
AgTech
Biotechnology
Late Stage Venture
41M30 Jul 2019 Belgium, Ghent

Precirix

Biotechnology
Early Stage Venture
43M15 Nov 2018 Belgium, City of Brussels
News
Anjarium Biosciences Raises $61M in Series A Financing
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies. – Series A funding closed at $61m. – The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). – The new investment will be used to advance the company’s pipeline programs towards clinical development. Read more
Anjarium Biosciences Raises $61M in Series A Financing
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies. – Series A funding closed at $61m. – The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). – The new investment will be used to advance the company’s pipeline programs towards clinical development. Read more

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Gimv?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: